标题
Towards precision medicine for AML
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-18
DOI
10.1038/s41571-021-00509-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
- (2021) Thomas Cluzeau et al. JOURNAL OF CLINICAL ONCOLOGY
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study
- (2020) Courtney D. DiNardo et al. BLOOD
- Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
- (2020) Hannah J. Uckelmann et al. SCIENCE
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients
- (2020) Shanshan Pei et al. Cancer Discovery
- Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
- (2020) Mark P. Chao et al. Frontiers in Oncology
- Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
- (2020) Guillermo Garcia-Manero et al. BLOOD
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
- (2020) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
- (2020) Curtis Andrew Lachowiez et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapidly Switchable Universal CAR-T cells for Treatment of CD123-positive Leukemia
- (2020) Simon Loff et al. Molecular Therapy-Oncolytics
- Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
- (2020) Chong Chyn Chua et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
- (2020) Carsten Riether et al. NATURE MEDICINE
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
- (2020) Jayakumar Vadakekolathu et al. Science Translational Medicine
- Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention
- (2020) Hannah J. Uckelmann et al. Stem Cell Reports
- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
- (2020) Sung Choe et al. Blood Advances
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- (2020) Geoffrey L Uy et al. BLOOD
- Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial
- (2020) Silke Kapp-Schwoerer et al. BLOOD
- Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
- (2020) Eytan M. Stein et al. BLOOD
- Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
- (2020) Alison R. Walker et al. CLINICAL CANCER RESEARCH
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
- (2020) Amy Burd et al. NATURE MEDICINE
- Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
- (2020) Kiyomi Morita et al. Nature Communications
- Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
- (2020) Maria Teresa Voso et al. Blood Advances
- Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
- (2020) Jan Philipp Bewersdorf et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
- (2019) Haijiao Zhang et al. Nature Communications
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
- (2019) Lina Han et al. HAEMATOLOGICA
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
- (2019) Xufeng Chen et al. Cancer Discovery
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
- (2019) Steffen Boettcher et al. SCIENCE
- Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies
- (2019) Manish R. Patel et al. BLOOD
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study
- (2019) Alexander E. Perl et al. BLOOD
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
- (2019) Elise Fournier et al. BLOOD
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
- (2019) Andrei V. Krivtsov et al. CANCER CELL
- Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
- (2019) Szymon Klossowski et al. JOURNAL OF CLINICAL INVESTIGATION
- The growing landscape of FLT3 inhibition in AML
- (2019) Catherine C. Smith Hematology-American Society of Hematology Education Program
- Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia
- (2018) Brenda Chyla et al. AMERICAN JOURNAL OF HEMATOLOGY
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
- (2018) Silvia Maifrede et al. BLOOD
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- IDH1/2Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
- (2018) Remco J. Molenaar et al. CLINICAL CANCER RESEARCH
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
- (2018) Qiang Zhang et al. Cell Death & Disease
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
- (2018) Eytan M. Stein et al. BLOOD
- Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
- (2018) Richard F. Schlenk et al. BLOOD
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
- (2018) Courtney L. Jones et al. CANCER CELL
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
- (2018) Hartmut Döhner et al. LEUKEMIA
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
- (2018) James J. Harding et al. Cancer Discovery
- Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
- (2017) Lars Bullinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
- (2017) T-C Teh et al. LEUKEMIA
- A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
- (2017) G Garcia-Manero et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells
- (2016) Nobuaki Fukushima et al. CANCER SCIENCE
- CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
- (2016) Carsten Riether et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
- (2016) M. W. M. Ku hn et al. Cancer Discovery
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
- (2015) Dmitry Borkin et al. CANCER CELL
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
- (2013) M. Casucci et al. BLOOD
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting hedgehog in hematologic malignancy
- (2012) D. A. Irvine et al. BLOOD
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- (2011) F. G. Rucker et al. BLOOD
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
- (2011) M. Jan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
- (2010) Maria E. Figueroa et al. CANCER CELL
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia
- (2009) X. Zhao et al. HAEMATOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now